Novel immunotherapies in multiple myeloma - chances and challenges

被引：24

作者：

Rasche, Leo ^{[1
,2
]}

Wasch, Ralph ^{[3
]}

Munder, Markus ^{[4
,5
]}

Goldschmidt, Hartmut ^{[6
,7
]}

Raab, Marc S. ^{[6
,8
]}

机构：

[1] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[2] Univ Hosp Wurzburg, Mildred Scheel Early Career Ctr, Wurzburg, Germany

[3] Univ Freiburg, Fac Med, Univ Med Ctr, Dept Internal Med 1, Freiburg, Germany

[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany

[5] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy, Mainz, Germany

[6] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[7] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[8] German Canc Res Ctr, CCU Mol Hematol Oncol, Heidelberg, Germany

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 10期

关键词：

T-CELL THERAPY; CAR-T; EXPRESSION; CD38;

D O I：

10.3324/haematol.2020.266858

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple myeloma. We discuss the pivotal questions to be addressed as these new immunotherapies become standard agents in the management of multiple myeloma. We also focus on the selection of patients for these therapies and speculate as to how best to individualize treatment approaches. We see these novel immunotherapies as representing a paradigm shift. However, despite the promising preliminary data, many open issues remain to be evaluated in future trials.

引用

页码：2555 / 2565

页数：11

共 50 条

[21] "Off-the-shelf" immunotherapies for multiple myeloma
Mohammed, Turab
Mailankody, Sham
SEMINARS IN ONCOLOGY, 2022, 49 (01) : 60 - 68
[22] Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
C. S. Chim
S. K. Kumar
R. Z. Orlowski
G. Cook
P. G. Richardson
M. A. Gertz
S. Giralt
M. V. Mateos
X. Leleu
K. C. Anderson
Leukemia, 2019, 33 : 1058 - 1059
[23] Immunotherapy for multiple myeloma: new chances and hope
Jingyu Xu
Gang An
Lugui Qiu
Cancer Biology & Medicine, 2023, (10) : 695 - 700
[24] Immunotherapy for multiple myeloma: new chances and hope
Xu, Jingyu
An, Gang
Qiu, Lugui
CANCER BIOLOGY & MEDICINE, 2023, 20 (10) : 695 - 700
[25] Immunotherapy for multiple myeloma: new chances and hope
Jingyu Xu
Gang An
Lugui Qiu
Cancer Biology & Medicine, 2023, 20 (10) : 695 - 700
[26] Immunotherapies targeting CD38 in Multiple Myeloma
Atanackovic, Djordje
Steinbach, Mary
Radhakrishnan, Sabarinath Venniyil
Luetkens, Tim
ONCOIMMUNOLOGY, 2016, 5 (11):
[27] Advances in the Development of Vaccines and Other Immunotherapies for Multiple Myeloma
Avigan, David E.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (12) : 670 - 673
[28] CT103A, a forward step in multiple myeloma immunotherapies
Xu, Jie
Melenhorst, J. Joseph
BLOOD SCIENCE, 2021, 3 (02): : 59 - 61
[29] Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
Nishida, Hiroko
CANCERS, 2021, 13 (11)
[30] Managing side effects: guidance for use of immunotherapies in multiple myeloma
Liang, Emily C.
Sidana, Surbhi
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2023, (01) : 348 - 356

← 1 2 3 4 5 →